{"id":"W3156148127","doi":"10.1158/1078-0432.ccr-20-4746","title":"Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":348,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Melanoma; Cancer; Antibody; Lung cancer; Gastroenterology; Oncology; Colorectal cancer; Ovarian cancer; Immunology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005360138,0.000300576,0.001608272,0.0003764595,0.0001673064,0.00003753573,0.0004630569,0.0007197185,0.0003123016],"category_scores_gemma":[0.001027471,0.0002634714,0.0001446896,0.001006689,0.002099574,0.000313374,0.0002807694,0.001985209,0.00001580678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008279824,"about_ca_system_score_gemma":0.001316458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001253633,"about_ca_topic_score_gemma":0.006090857,"domain_scores_codex":[0.9915034,0.00406882,0.001911653,0.001321996,0.0002199363,0.000974181],"domain_scores_gemma":[0.9970151,0.001084438,0.0003694702,0.0007714716,0.0005856935,0.0001738675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1074899,0.01746177,0.6581275,0.0001364491,0.0002044603,0.0004103203,0.0002772462,0.00002847185,0.1628009,0.0004032024,0.0001473413,0.05251246],"study_design_scores_gemma":[0.2660609,0.03276844,0.6683549,0.0004873524,0.00005587136,0.0001102508,0.0008687605,0.0002194882,0.02757274,0.0004763735,0.002400549,0.0006243301],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949802,0.002359276,0.00001813899,0.0005660085,0.0008346785,0.0009371916,0.00007459218,0.00003045324,0.0001995317],"genre_scores_gemma":[0.9928138,0.006046572,0.00007511715,0.0001220194,0.0001639237,0.0000805016,0.0005363526,0.00004056576,0.0001211516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.158571,"threshold_uncertainty_score":0.9999818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1544985978344693,"score_gpt":0.553803520585191,"score_spread":0.3993049227507217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}